The US FDA has proposed adding bemotrizinol to its list of approved sunscreen active ingredients. This move, announced on December 11, 2025, aims to modernise regulations and provide Americans with better UV protection, an update not seen in decades.
Bemotrizinol offers broad-spectrum protection with low systemic absorption, according to the FDA. It's generally recognised as safe and effective for adults and children over six months, rarely causing irritation. DSM Nutritional Products LLC submitted the request for its use at concentrations up to six percent.
This development is significant for UK salon and beauty business owners. The current US market has limited options for formulators. Bemotrizinol, praised by experts for its UVA protection and photostability, could allow for more effective and elegant sunscreen formulations. Its ability to stabilise other filters like avobenzone may address consumer concerns about real-world SPF discrepancies.
Dermatologists highlight its potential benefit for conditions like melasma and hyperpigmentation, particularly in skin of colour patients. The ingredient's minimal irritation and absorption profile also reassure safety concerns.
The American Academy of Dermatology Association supports this FDA initiative, noting the US trails other countries in approved sunscreen ingredients. The public comment period remains open for the proposal, which could see bemotrizinol added to OTC Monograph M020.
